rituximab

January 23, 2020

Polivy Triple Combo Approved in Europe for Select Patients with Advanced DLBCL

News

The European Commission has conditionally approved Roche’s Polivy (polatuzumab vedotin), in combination with rituximab and bendamustine, to treat people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for a hematopoietic (blood) stem cell transplant (HSCT). ... Read more

January 9, 2020January 15, 2020

Venclexta-rituximab Combo Shows Long-term Survival Benefits for Relapsed CLL Patients

News

A combination of Venclexta (venetoclax) and rituximab continues to significantly reduce the risk of disease progression or death in relapsed or refractory chronic lymphocytic leukemia (CLL) patients two years after completing ... Read more

January 2, 2020January 2, 2020

Revlimid-Rituximab Combo Approved in Europe for Previously Treated Follicular Lymphoma

News

The European Commission has approved Bristol-Myers Squibb‘s Revlimid (lenalidomide) in combination with rituximab to treat adults with follicular lymphoma who are no longer responding to other therapies. The combination is the first chemotherapy-free treatment ... Read more

December 5, 2019

CHMP Favors Revlimid-Rituximab Combo for Advanced Follicular Lymphoma Patients in EU

News

A branch of the European Medicines Agency voiced support for Revlimid (lenalidomide) in combination with rituximab becoming a treatment option for adults with follicular lymphoma who responded poorly to, or whose disease returned ... Read more

October 24, 2019October 24, 2019

Follicular Lymphoma Patients Being Recruited for Phase 2 Trial of Aliqopa-Rituximab Combo

News

A Phase 2 clinical trial is recruiting patients with untreated follicular lymphoma — the most common type of non-Hodgkin’s lymphoma — to study a combination of Aliqopa (copanlisib) and rituximab. The trial ... Read more

May 3, 2019

Forty Seven, Genentech Continue to Test Triple Immunotherapy Combo in DLBCL

News

Forty Seven and Genentech are extending their agreement to include a third clinical trial evaluating a combination of the investigational 5F9 plus Rituxan (rituximab) and Tecentriq (atezolizumab) in patients with diffuse large B-cell lymphoma (DLBCL). The decision builds on prior ... Read more

March 28, 2019

Revlimid/Rituxan Combo Shows Promise in Follicular, Marginal Zone Lymphomas

News

Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a combination ... Read more

February 11, 2019

Rituxan Plus Chemo Fails to Benefit Newly Diagnosed Primary CNS Lymphoma Patients in Clinical Trial

News

Adding Rituxan (rituximab) to standard first-line chemotherapy did not improve disease outcomes for people with primary central nervous system (CNS) lymphoma in a Phase 3 clinical trial, results show. The ... Read more

December 14, 2018

Truxima Shows Safety, Efficacy Comparable to Rituxan in Advanced Follicular Lymphoma

News

Truxima (rituximab-abbs), a biosimilar to Rituxan (rituxumab), has similar safety and efficacy as the original product in patients with advanced follicular lymphoma after two years, results from a Phase 3 ... Read more

December 5, 2018

5F9-Rituxan Combo Eliminates Tumors in One-third of DLBCL, Follicular Lymphoma Patients

News

A combination of Forty Seven‘s macrophage checkpoint inhibitor Hu5F9-G4 and Rituxan (rituximab) is safe and completely eliminated tumors in one-third of non-Hodgkin’s lymphoma patients included in a Phase 1b trial. The trial, ... Read more